Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.
Related Insights
Instead of expanding at its New Jersey headquarters, Legend Biotech opened its new R&D center in Philadelphia. This strategic move aims to attract specialized scientific talent by deliberately locating in a key innovation hub for cell therapy, demonstrating a "go to the talent" growth strategy.
Contrary to the remote-first trend, Crisp.ai's founder advises against a fully distributed model for initial product development. He argues for gathering the core team in one physical location to harness the energy and efficiency of in-person collaboration. Distributed teams are better suited for iterating on an already established product.
CZI's Biohub model hinges on a simple principle: physically seating biologists and engineers from different institutions (Stanford, UCSF, Berkeley) together. This direct proximity fosters collaboration and creates hybrid experts, overcoming the institutional silos often reinforced by traditional grant-based funding.
The company leverages its remote structure by hiring strategically. A Spanish team is located near suppliers for better sourcing and relationships, while a British team focuses on the consumer market. This intentional geographic distribution optimizes both supply chain and marketing efforts.
Actuate Therapeutics maintains high capital efficiency by keeping its full-time headcount low. The company is built around a trusted core team and supplemented by an extensive stable of "best of breed" consultants who are engaged on an as-needed basis, minimizing overhead costs.
Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.
The shift to remote work unlocked a global talent pool. For specialized roles, the advantage of hiring the best possible person, regardless of location, is far greater than the benefits of in-person collaboration. The leadership challenge shifts from managing location to enabling distributed top-tier talent.
Instead of creating a tech sector from scratch, the most effective path is to identify and invest in tech niches adjacent to a city's existing industries (e.g., Energy Tech for an oil town). This leverages existing talent, infrastructure, and supply chains, making the transition more natural and sustainable.
To avoid the pitfalls of scale in R&D, Eli Lilly operates small, focused labs of 300-400 people. These 'internal biotechs' have mission focus and autonomy, while leveraging the parent company's scale for clinical trials and distribution.
CZI's Biohub model fosters cross-disciplinary breakthroughs by physically sitting engineers and biologists together. This simple organizational tactic encourages informal communication and collaboration, proving more effective at solving complex problems than formal structures and reporting lines.
